Trulicity vs Ozempic: Comparing Weekly Doses, Uses, and Formulas

Trulicity vs Ozempic at a Glance

The primary difference between Trulicity and Ozempic centers on their active chemical structures, weekly dose increments, approved medical indications, and missed-dose guidelines.

Both medications require subcutaneous injection once per week. Neither label compares the two, so the choice is the prescriber's.

Molecular Structure and Drug Construction

Trulicity and Ozempic use distinct active molecules that share sequence similarities with native human glucagon-like peptide-1.

Ozempic contains semaglutide, which is a GLP-1 analogue with 94 percent sequence homology to human GLP-1. The peptide backbone of semaglutide is produced by yeast fermentation and has a molecular weight of 4113.58 grams per mole. For an in-depth breakdown of how this molecule is classified, see our guide on is Ozempic a peptide.

Trulicity contains dulaglutide, which is engineered as a fusion protein consisting of two identical disulfide-linked chains. Each chain contains a GLP-1 analog sequence linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain. The GLP-1 portion of dulaglutide shares 90 percent sequence homology to native human GLP-1 (7-37). Dulaglutide has an approximate molecular weight of 63 kilodaltons and is produced using Chinese hamster ovary cell culture.

Dosing Ladders and Pen Strengths

The dosing ladder for Ozempic spans 0.25 mg to 2 mg weekly, whereas Trulicity titrates across adult doses ranging from 0.75 mg to 4.5 mg weekly.

Patients initiating Ozempic start at 0.25 mg injected once weekly for 4 weeks. The prescriber then increases the dose to 0.5 mg once weekly. If additional glycemic control is required, raise the dose to 1 mg weekly after at least 4 weeks on 0.5 mg. The maximum recommended dose is 2 mg once weekly after at least 4 weeks on 1 mg. To review the full escalation schedule, visit our Ozempic dosage timeline guide.

Adult patients starting Trulicity begin with 0.75 mg once weekly. After 4 weeks, the prescriber may increase the dose to 1.5 mg once weekly. If more glycemic control is needed, increase in 1.5 mg steps after at least 4 weeks on the current dose. The maximum recommended dose is 4.5 mg once weekly. Trulicity also includes a pediatric dosing protocol: patients 10 years of age and older start at 0.75 mg weekly, with a maximum dose of 1.5 mg weekly. Trulicity pens are single-dose devices available in strengths of 0.75 mg, 1.5 mg, 3 mg, and 4.5 mg.

Approved Indications and Patient Populations

Ozempic and Trulicity share core indications for type 2 diabetes glycemic control and cardiovascular risk reduction, but their labels diverge regarding chronic kidney disease and pediatric care.

Both drugs are approved as adjuncts to diet and exercise to improve blood sugar control in adults with type 2 diabetes. However, Trulicity is also approved for pediatric patients aged 10 years and older. Ozempic is approved only for adults.

For cardiovascular protection, both medications hold approvals to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Trulicity extends this cardiovascular indication to adults with type 2 diabetes who possess multiple cardiovascular risk factors even without established cardiovascular disease.

Ozempic holds an additional indication that Trulicity lacks. The FDA approved Ozempic to reduce the risk of sustained estimated glomerular filtration rate (eGFR) decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease. Trulicity does not hold an indication for chronic kidney disease progression.

Adverse Reactions and Boxed Warnings

Gastrointestinal symptoms represent the most common adverse reactions reported on the prescribing labels for both Trulicity and Ozempic.

Adverse reactions occurring in 5 percent or more of patients receiving Ozempic include nausea, vomiting, diarrhea, abdominal pain, and constipation. For Trulicity, reactions reported in 5 percent or more of patients include nausea, diarrhea, vomiting, abdominal pain, and decreased appetite. Constipation appears frequently in Ozempic reports, while decreased appetite is cited specifically on the Trulicity label. Readers can learn more about managing digestive symptoms in our GLP-1 side effects overview.

Both labels carry a boxed warning regarding thyroid C-cell tumors. In animal studies, both dulaglutide and semaglutide caused thyroid C-cell tumors in rodents, though the relevance in humans remains undetermined. Both medications are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients taking either medication should contact their physician if they notice a mass in the neck, persistent hoarseness, trouble swallowing, or shortness of breath.

Administration and Missed-Dose Guidelines

Patients administer both Trulicity and Ozempic as weekly subcutaneous injections, but each drug operates under different rules for missed doses.

Each medication is injected subcutaneously into the abdomen, thigh, or upper arm once weekly at any time of day, with or without food. When using Ozempic, patients should rotate injection sites each week when administering doses in the same body region. when Ozempic is administered alongside insulin, the two drugs must be injected separately and never mixed. Ozempic and insulin may be injected in the same body region, provided the injection sites are not adjacent.

If a dose of Ozempic is missed, the patient should administer it as soon as possible within 5 days of the missed dose. If more than 5 days have elapsed, skip the missed dose. Resume on the regular injection day. Patients can change their regular weekly injection day for Ozempic as long as at least 2 days (more than 48 hours) separate two doses.

If a dose of Trulicity is missed, the patient should administer it as soon as possible if there are at least 3 days (72 hours) remaining until the next scheduled dose.

Choosing Between the Two

For pediatric patients 10 years of age and older with type 2 diabetes, Trulicity is the option with an approved pediatric indication. Trulicity offers single-dose pens across four strengths. Other GLP-1 medications and comparisons exist across the diabetes landscape, such as Ozempic vs Mounjaro, Rybelsus vs Ozempic, Wegovy vs Trulicity, and Zepbound vs Trulicity.

What to Look For in a Body-Composition Scale

A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.

GE Smart Scale for Body Weight: 8-Electrode Digital Bathroom Scale for Weight Fat BMI Muscle Mass Full Body Composition Analyzer 50 Measurements Bluetooth Highly Accurate Weighing Machine 400lb Black

GE

View on Amazon →

Etekcity Smart Scale for Body Weight, FSA&HSA Eligible, Bathroom Digital Weighing Scale with BMI, Body Fat, Muscle Mass, Accurate Bluetooth Home User Health Equipment Sync Apps, LED, Tempered glass

Etekcity

View on Amazon →